디지털 바이오마커 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031년)

Persistence Market Research has recently released a comprehensive report on the global Digital Biomarkers Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report delivers a detailed understanding of the market landscape, empowering stakeholders to make well-informed decisions.

Key Insights:

• Digital Biomarkers Market Size (2024E): US$2.7 Bn
• Projected Market Value (2031F): US$10.6 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 21.8%

Digital Biomarkers Market - Report Scope:

The Digital Biomarkers Market encompasses quantifiable, non-invasive, objective, and continuous measurement of physiological and behavioral measures collected through digital devices such as wearables, portable, digestible, or implantable technology. These biomarkers offer valuable insights into disease progression, treatment efficacy, and patient response in real-world settings. The market growth is propelled by advancements in wearable technology, mobile health applications, and AI algorithms that analyze data generated by digital health tools. The ongoing development of digital biomarkers is revolutionizing personalized medicine, remote patient monitoring, and early disease detection, significantly improving healthcare delivery and clinical trial efficiency.

Market Growth Drivers:

The demand for personalized, remote patient care is a significant driver for the digital biomarkers market, enabling a shift towards value-based healthcare models. Real-time tracking of physiological parameters and environmental factors provides a comprehensive health view, allowing for tailored treatment plans and better disease management. Additionally, the use of cutting-edge technology like AI and machine learning (ML) enhances the precision and patient-centricity of clinical trials by capturing real-time data, minimizing site visits, and improving data quality.

Market Restraints:

Challenges include complex reimbursement systems and evolving regulations for digital therapeutics. Uncertainties surrounding reimbursement frameworks can hinder the adoption of digital biomarkers. Navigating regulatory compliance across regions requires robust resources to meet stringent data privacy laws, such as GDPR in Europe and HIPAA in the US. Moreover, standardizing digital biomarkers across various healthcare settings is complicated and may impact their value.

Market Opportunities:

Significant opportunities arise from the use of blockchain for enhanced data security and collaborations with healthcare providers, technology firms, and research institutions. Blockchain technology can protect sensitive health data from breaches, while partnerships accelerate the development of robust biomarkers and foster innovation. These trends support precision medicine by optimizing treatment strategies and improving clinical outcomes.

Key Questions Answered in the Report:

• What are the main factors driving the growth of the global Digital Biomarkers Market?
• Which therapeutic areas are witnessing the highest adoption of digital biomarkers?
• How do regulations and reimbursement policies impact the digital biomarkers market?
• Who are the leading players in the Digital Biomarkers Market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future outlooks for the global Digital Biomarkers Market?

Competitive Intelligence and Business Strategy:

Key players in the global Digital Biomarkers Market, such as ActiGraph LLC, AliveCor Inc., and Biogen, focus on innovation, strategic partnerships, and product development. Companies are investing in advanced technologies like AI, ML, and blockchain to develop accurate and reliable biomarkers, ensuring compliance with evolving regulatory frameworks. Collaboration with research institutions is critical for maintaining market leadership and addressing healthcare challenges.

Key Companies Profiled:

• ActiGraph LLC
• AliveCor Inc.
• Koneksa Health
• Altoida Inc.
• Biogen
• Empatica Inc.
• Vivo Sense
• IXICO plc
• Aural Analytic
• Huma
• Sonde Health, Inc.

Digital Biomarkers Market Segmentation

By Component

• Data Collection Tools
• Data Integration Software

By Therapeutic Area

• Cardiovascular and Metabolic Disorders (CVMD)
• Neurodegenerative Disorders
• Diabetes
• Respiratory Disorders
• Sleep and Movement Disorders
• Others

By Clinical Practice

• Diagnostic Digital Biomarkers
• Monitoring Digital Biomarkers
• Predictive and Prognostic Digital Biomarkers
• Others

By End User

• Healthcare Consumers
• Healthcare Providers
• Others

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Digital Biomarkers Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Technology Assessment
• 3.3. Regulatory Landscape
• 3.4. Supply Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Price Analysis, 2024A

• 4.1. Key Highlights
• 4.2. Key Factors Impacting Therapeutic Area Prices
• 4.3. Pricing Analysis, By Component
• 4.4. Regional Prices and Therapeutic Area Preferences

5. Global Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 5.1. Key Highlights
  • 5.1.1. Market Volume (Units) Projections
  • 5.1.2. Market Size (US$ Mn) and Y-o-Y Growth
  • 5.1.3. Absolute $ Opportunity
• 5.2. Market Size (US$ Mn) Analysis and Forecast
  • 5.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2023
  • 5.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2024-2031
• 5.3. Global Digital Biomarkers Market Outlook: Component
  • 5.3.1. Introduction / Key Findings
  • 5.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, By Component, 2019-2023
  • 5.3.3. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
    • 5.3.3.1. Data Collection Tools
      • 5.3.3.1.1. Wearable Devices
      • 5.3.3.1.2. Implantable
      • 5.3.3.1.3. Mobile Applications
      • 5.3.3.1.4. Others
    • 5.3.3.2. Data Integration Software
• 5.4. Market Attractiveness Analysis: Component
• 5.5. Global Digital Biomarkers Market Outlook: Therapeutic Area
  • 5.5.1. Introduction / Key Findings
  • 5.5.2. Historical Market Size (US$ Mn) Analysis, By Therapeutic Area, 2019-2023
  • 5.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
    • 5.5.3.1. Cardiovascular and Metabolic Disorders (CVMD)
    • 5.5.3.2. Neurodegenerative Disorders
    • 5.5.3.3. Diabetes
    • 5.5.3.4. Respiratory Disorders
    • 5.5.3.5. Sleep and Movement Disorders
    • 5.5.3.6. Others
• 5.6. Market Attractiveness Analysis: Therapeutic Area
• 5.7. Global Digital Biomarkers Market Outlook: Clinical Practice
  • 5.7.1. Introduction / Key Findings
  • 5.7.2. Historical Market Size (US$ Mn) Analysis, By Clinical Practice, 2019-2023
  • 5.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
    • 5.7.3.1. Diagnostic Digital Biomarkers
    • 5.7.3.2. Monitoring Digital Biomarkers
    • 5.7.3.3. Predictive and Prognostic Digital Biomarkers
    • 5.7.3.4. Others
• 5.8. Market Attractiveness Analysis: Clinical Practice
• 5.9. Global Digital Biomarkers Market Outlook: End User
  • 5.9.1. Introduction / Key Findings
  • 5.9.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
  • 5.9.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
    • 5.9.3.1. Healthcare Consumers
    • 5.9.3.2. Healthcare Providers
    • 5.9.3.3. Others
• 5.10. Market Attractiveness Analysis: End User

6. Global Digital Biomarkers Market Outlook: Region

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024-2031
  • 6.3.1. North America
  • 6.3.2. Europe
  • 6.3.3. East Asia
  • 6.3.4. South Asia and Oceania
  • 6.3.5. Latin America
  • 6.3.6. Middle East & Africa
• 6.4. Market Attractiveness Analysis: Region

7. North America Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 7.2.1. By Country
  • 7.2.2. By Component
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By Clinical Practice
  • 7.2.5. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 7.3.1. U.S.
  • 7.3.2. Canada
• 7.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
  • 7.4.1. Data Collection Tools
    • 7.4.1.1. Wearable Devices
    • 7.4.1.2. Implantable
    • 7.4.1.3. Mobile Applications
    • 7.4.1.4. Others
  • 7.4.2. Data Integration Software
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 7.5.1. Cardiovascular and Metabolic Disorders (CVMD)
  • 7.5.2. Neurodegenerative Disorders
  • 7.5.3. Diabetes
  • 7.5.4. Respiratory Disorders
  • 7.5.5. Sleep and Movement Disorders
  • 7.5.6. Others
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
  • 7.6.1. Diagnostic Digital Biomarkers
  • 7.6.2. Monitoring Digital Biomarkers
  • 7.6.3. Predictive and Prognostic Digital Biomarkers
  • 7.6.4. Others
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 7.7.1. Healthcare Consumers
  • 7.7.2. Healthcare Providers
  • 7.7.3. Others
• 7.8. Market Attractiveness Analysis

8. Europe Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 8.2.1. By Country
  • 8.2.2. By Component
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By Clinical Practice
  • 8.2.5. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 8.3.1. Germany
  • 8.3.2. France
  • 8.3.3. U.K.
  • 8.3.4. Italy
  • 8.3.5. Spain
  • 8.3.6. Russia
  • 8.3.7. Turkiye
  • 8.3.8. Rest of Europe
• 8.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
  • 8.4.1. Data Collection Tools
    • 8.4.1.1. Wearable Devices
    • 8.4.1.2. Implantable
    • 8.4.1.3. Mobile Applications
    • 8.4.1.4. Others
  • 8.4.2. Data Integration Software
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 8.5.1. Cardiovascular and Metabolic Disorders (CVMD)
  • 8.5.2. Neurodegenerative Disorders
  • 8.5.3. Diabetes
  • 8.5.4. Respiratory Disorders
  • 8.5.5. Sleep and Movement Disorders
  • 8.5.6. Others
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
  • 8.6.1. Diagnostic Digital Biomarkers
  • 8.6.2. Monitoring Digital Biomarkers
  • 8.6.3. Predictive and Prognostic Digital Biomarkers
  • 8.6.4. Others
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 8.7.1. Healthcare Consumers
  • 8.7.2. Healthcare Providers
  • 8.7.3. Others
• 8.8. Market Attractiveness Analysis

9. East Asia Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 9.2.1. By Country
  • 9.2.2. By Component
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By Clinical Practice
  • 9.2.5. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. South Korea
• 9.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
  • 9.4.1. Data Collection Tools
    • 9.4.1.1. Wearable Devices
    • 9.4.1.2. Implantable
    • 9.4.1.3. Mobile Applications
    • 9.4.1.4. Others
  • 9.4.2. Data Integration Software
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 9.5.1. Cardiovascular and Metabolic Disorders (CVMD)
  • 9.5.2. Neurodegenerative Disorders
  • 9.5.3. Diabetes
  • 9.5.4. Respiratory Disorders
  • 9.5.5. Sleep and Movement Disorders
  • 9.5.6. Others
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
  • 9.6.1. Diagnostic Digital Biomarkers
  • 9.6.2. Monitoring Digital Biomarkers
  • 9.6.3. Predictive and Prognostic Digital Biomarkers
  • 9.6.4. Others
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 9.7.1. Healthcare Consumers
  • 9.7.2. Healthcare Providers
  • 9.7.3. Others
• 9.8. Market Attractiveness Analysis

10. South Asia & Oceania Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 10.2.1. By Country
  • 10.2.2. By Component
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By Clinical Practice
  • 10.2.5. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 10.3.1. India
  • 10.3.2. Southeast Asia
  • 10.3.3. ANZ
  • 10.3.4. Rest of South Asia & Oceania
• 10.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
  • 10.4.1. Data Collection Tools
    • 10.4.1.1. Wearable Devices
    • 10.4.1.2. Implantable
    • 10.4.1.3. Mobile Applications
    • 10.4.1.4. Others
  • 10.4.2. Data Integration Software
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 10.5.1. Cardiovascular and Metabolic Disorders (CVMD)
  • 10.5.2. Neurodegenerative Disorders
  • 10.5.3. Diabetes
  • 10.5.4. Respiratory Disorders
  • 10.5.5. Sleep and Movement Disorders
  • 10.5.6. Others
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
  • 10.6.1. Diagnostic Digital Biomarkers
  • 10.6.2. Monitoring Digital Biomarkers
  • 10.6.3. Predictive and Prognostic Digital Biomarkers
  • 10.6.4. Others
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 10.7.1. Healthcare Consumers
  • 10.7.2. Healthcare Providers
  • 10.7.3. Others
• 10.8. Market Attractiveness Analysis

11. Latin America Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 11.2.1. By Country
  • 11.2.2. By Component
  • 11.2.3. By Therapeutic Area
  • 11.2.4. By Clinical Practice
  • 11.2.5. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 11.3.1. Brazil
  • 11.3.2. Mexico
  • 11.3.3. Rest of Latin America
• 11.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
  • 11.4.1. Data Collection Tools
    • 11.4.1.1. Wearable Devices
    • 11.4.1.2. Implantable
    • 11.4.1.3. Mobile Applications
    • 11.4.1.4. Others
  • 11.4.2. Data Integration Software
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 11.5.1. Cardiovascular and Metabolic Disorders (CVMD)
  • 11.5.2. Neurodegenerative Disorders
  • 11.5.3. Diabetes
  • 11.5.4. Respiratory Disorders
  • 11.5.5. Sleep and Movement Disorders
  • 11.5.6. Others
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
  • 11.6.1. Diagnostic Digital Biomarkers
  • 11.6.2. Monitoring Digital Biomarkers
  • 11.6.3. Predictive and Prognostic Digital Biomarkers
  • 11.6.4. Others
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 11.7.1. Healthcare Consumers
  • 11.7.2. Healthcare Providers
  • 11.7.3. Others
• 11.8. Market Attractiveness Analysis

12. Middle East & Africa Digital Biomarkers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 12.1. Key Highlights
• 12.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 12.2.1. By Country
  • 12.2.2. By Component
  • 12.2.3. By Therapeutic Area
  • 12.2.4. By Clinical Practice
  • 12.2.5. By End User
• 12.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 12.3.1. GCC Countries
  • 12.3.2. Egypt
  • 12.3.3. South Africa
  • 12.3.4. Northern Africa
  • 12.3.5. Rest of Middle East & Africa
• 12.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Component, 2024-2031
  • 12.4.1. Data Collection Tools
    • 12.4.1.1. Wearable Devices
    • 12.4.1.2. Implantable
    • 12.4.1.3. Mobile Applications
    • 12.4.1.4. Others
  • 12.4.2. Data Integration Software
• 12.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 12.5.1. Cardiovascular and Metabolic Disorders (CVMD)
  • 12.5.2. Neurodegenerative Disorders
  • 12.5.3. Diabetes
  • 12.5.4. Respiratory Disorders
  • 12.5.5. Sleep and Movement Disorders
  • 12.5.6. Others
• 12.6. Current Market Size (US$ Mn) Analysis and Forecast, By Clinical Practice, 2024-2031
  • 12.6.1. Diagnostic Digital Biomarkers
  • 12.6.2. Monitoring Digital Biomarkers
  • 12.6.3. Predictive and Prognostic Digital Biomarkers
  • 12.6.4. Others
• 12.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 12.7.1. Healthcare Consumers
  • 12.7.2. Healthcare Providers
  • 12.7.3. Others
• 12.8. Market Attractiveness Analysis

13. Competition Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. Market Structure
  • 13.2.1. Competition Intensity Mapping By Market
  • 13.2.2. Competition Dashboard
• 13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 13.3.1. ActiGraph LLC
    • 13.3.1.1. Overview
    • 13.3.1.2. Segments and Products
    • 13.3.1.3. Key Financials
    • 13.3.1.4. Market Developments
    • 13.3.1.5. Market Strategy
  • 13.3.2. AliveCor Inc.
    • 13.3.2.1. Overview
    • 13.3.2.2. Segments and Products
    • 13.3.2.3. Key Financials
    • 13.3.2.4. Market Developments
    • 13.3.2.5. Market Strategy
  • 13.3.3. Koneksa Health
    • 13.3.3.1. Overview
    • 13.3.3.2. Segments and Products
    • 13.3.3.3. Key Financials
    • 13.3.3.4. Market Developments
    • 13.3.3.5. Market Strategy
  • 13.3.4. Altoida Inc.
    • 13.3.4.1. Overview
    • 13.3.4.2. Segments and Products
    • 13.3.4.3. Key Financials
    • 13.3.4.4. Market Developments
    • 13.3.4.5. Market Strategy
  • 13.3.5. Biogen
    • 13.3.5.1. Overview
    • 13.3.5.2. Segments and Products
    • 13.3.5.3. Key Financials
    • 13.3.5.4. Market Developments
    • 13.3.5.5. Market Strategy
  • 13.3.6. Empatica Inc.
    • 13.3.6.1. Overview
    • 13.3.6.2. Segments and Products
    • 13.3.6.3. Key Financials
    • 13.3.6.4. Market Developments
    • 13.3.6.5. Market Strategy
  • 13.3.7. Vivo Sense
    • 13.3.7.1. Overview
    • 13.3.7.2. Segments and Products
    • 13.3.7.3. Key Financials
    • 13.3.7.4. Market Developments
    • 13.3.7.5. Market Strategy
  • 13.3.8. IXICO plc
    • 13.3.8.1. Overview
    • 13.3.8.2. Segments and Products
    • 13.3.8.3. Key Financials
    • 13.3.8.4. Market Developments
    • 13.3.8.5. Market Strategy
  • 13.3.9. Aural Analytic
    • 13.3.9.1. Overview
    • 13.3.9.2. Segments and Products
    • 13.3.9.3. Key Financials
    • 13.3.9.4. Market Developments
    • 13.3.9.5. Market Strategy
  • 13.3.10. Huma
    • 13.3.10.1. Overview
    • 13.3.10.2. Segments and Products
    • 13.3.10.3. Key Financials
    • 13.3.10.4. Market Developments
    • 13.3.10.5. Market Strategy
  • 13.3.11. Sonde Health, Inc.
    • 13.3.11.1. Overview
    • 13.3.11.2. Segments and Products
    • 13.3.11.3. Key Financials
    • 13.3.11.4. Market Developments
    • 13.3.11.5. Market Strategy
  • 13.3.12. Akili Interactive Labs, Inc.
    • 13.3.12.1. Overview
    • 13.3.12.2. Segments and Products
    • 13.3.12.3. Key Financials
    • 13.3.12.4. Market Developments
    • 13.3.12.5. Market Strategy
  • 13.3.13. Cambridge Cognition Ltd.
    • 13.3.13.1. Overview
    • 13.3.13.2. Segments and Products
    • 13.3.13.3. Key Financials
    • 13.3.13.4. Market Developments
    • 13.3.13.5. Market Strategy
  • 13.3.14. Dassault Systemes (Medidata)
    • 13.3.14.1. Overview
    • 13.3.14.2. Segments and Products
    • 13.3.14.3. Key Financials
    • 13.3.14.4. Market Developments
    • 13.3.14.5. Market Strategy
  • 13.3.15. Shimmer
    • 13.3.15.1. Overview
    • 13.3.15.2. Segments and Products
    • 13.3.15.3. Key Financials
    • 13.3.15.4. Market Developments
    • 13.3.15.5. Market Strategy
  • 13.3.16. Feel Therapeutics
    • 13.3.16.1. Overview
    • 13.3.16.2. Segments and Products
    • 13.3.16.3. Key Financials
    • 13.3.16.4. Market Developments
    • 13.3.16.5. Market Strategy
  • 13.3.17. Clario
    • 13.3.17.1. Overview
    • 13.3.17.2. Segments and Products
    • 13.3.17.3. Key Financials
    • 13.3.17.4. Market Developments
    • 13.3.17.5. Market Strategy
  • 13.3.18. Imagene AI
    • 13.3.18.1. Overview
    • 13.3.18.2. Segments and Products
    • 13.3.18.3. Key Financials
    • 13.3.18.4. Market Developments
    • 13.3.18.5. Market Strategy
  • 13.3.19. Brainomix
    • 13.3.19.1. Overview
    • 13.3.19.2. Segments and Products
    • 13.3.19.3. Key Financials
    • 13.3.19.4. Market Developments
    • 13.3.19.5. Market Strategy
  • 13.3.20. Kinsa Inc.
    • 13.3.20.1. Overview
    • 13.3.20.2. Segments and Products
    • 13.3.20.3. Key Financials
    • 13.3.20.4. Market Developments
    • 13.3.20.5. Market Strategy
  • 13.3.21. Pfizer Hellas S.A.
    • 13.3.21.1. Overview
    • 13.3.21.2. Segments and Products
    • 13.3.21.3. Key Financials
    • 13.3.21.4. Market Developments
    • 13.3.21.5. Market Strategy
  • 13.3.22. Human API
    • 13.3.22.1. Overview
    • 13.3.22.2. Segments and Products
    • 13.3.22.3. Key Financials
    • 13.3.22.4. Market Developments
    • 13.3.22.5. Market Strategy
  • 13.3.23. Evidation Health, Inc.
    • 13.3.23.1. Overview
    • 13.3.23.2. Segments and Products
    • 13.3.23.3. Key Financials
    • 13.3.23.4. Market Developments
    • 13.3.23.5. Market Strategy
  • 13.3.24. Verily
    • 13.3.24.1. Overview
    • 13.3.24.2. Segments and Products
    • 13.3.24.3. Key Financials
    • 13.3.24.4. Market Developments
    • 13.3.24.5. Market Strategy
  • 13.3.25. electronRx
    • 13.3.25.1. Overview
    • 13.3.25.2. Segments and Products
    • 13.3.25.3. Key Financials
    • 13.3.25.4. Market Developments
    • 13.3.25.5. Market Strategy

14. Appendix

• 4.1. Research Methodology
• 4.2. Research Assumptions
• 4.3. Acronyms and Abbreviations